TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05113589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBM TREATMENT
Description: Participants randomized to this treatment will receive a whole body PBM treatment using a NovoTHOR® whole body light bed. For each treatment session, participants will lie supine in the treatment bed for 20 minutes, with no or minimal attire (underwear). Treatment sessions will be three times weekly for a period of 4 weeks, totalling 12 treatment sessions

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO PBM
Description: The placebo feature of the whole body PBM bed provides controls that select active or placebo (sham) treatments in a way undetectable by participant, operator or observers, such that no-one is aware whether the participant is receiving an active or placebo treatment. There is a switch box that randomises participants to active or placebo; no other randomisation is necessary.
Study: NCT05362526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFOT using AIRVO2
Description: The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases. The subjects in this group will receive HFOT at a flow rate of 60-30L liters per minute, maximum concentration of 40%, which will be titrated by bedside nurse to maintain an oxygen saturation of 92% or greater (unless there is a history of COPD and then the clinician can recommend \>88%)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COT
Description: Subjects will be placed on aerosolized trach mask with cool humidification, and titrated to keep oxygen saturation \>92% (unless there is a history of COPD and then the clinician can recommend \>88%)
Study: NCT05860816

Intervention type: OTHER
Intervention: Survey
Description: Survey aimed at finding out the barriers and facilitators that Spanish primary care physiotherapists have to implement pain neuroscience-based education programmes in patients with chronic pain.
Study: NCT06522932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-GRIP B
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-GRIP B
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional tumor biopsy
Description: Undergo optional tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional tumor biopsy
Description: Undergo optional tumor biopsy
Study: NCT05915871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicilli
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Tablet for oral administration
Study: NCT04823052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac (HLX-0201), dose strength 1
Description: Sulindac (HLX-0201) Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac (HLX-0201), dose strength 2
Description: Sulindac (HLX-0201) Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gaboxadol (HLX-0206)
Description: Gaboxadol (HLX-0206) Capsule
Study: NCT04883450

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: All enrolled participants will undergo magnetic resonance imaging (MRI) at their Baseline and 18-Month follow-up visit
Study: NCT05821608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Message variation 1
Description: Message before call letting member know they will be called (variation 1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Message variation 2
Description: Message before call letting member know they will be called (variation 2)
Study: NCT05028140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIEMONTE
Description: Piemonte association 1 coated tablet once a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PIEMONTE PLACEBO
Description: Placebo of Piemonte association 1 coated tablet once a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PIEMONTE PLACEBO
Description: Placebo of Piemonte association 1 coated tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMPAGLIFLOZIN
Description: Empagliflozin 25 mg 1 coated tablet once a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO EMPAGLIFLOZIN
Description: Placebo of empagliflozin 25 mg 1 coated tablet once a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PLACEBO EMPAGLIFLOZIN
Description: Placebo of empagliflozin 25 mg 1 coated tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PIOGLITAZONE
Description: Pioglitazone 30 mg 1 tablet once a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PLACEBO PIOGLITAZONE
Description: Placebo of pioglitazone 30 mg 1 tablet once a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO PIOGLITAZONE
Description: Placebo of pioglitazone 30 mg 1 tablet once a day
Study: NCT05363241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency in classical targets (CRF-CT)
Description: Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial. The participant will not be able to follow the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency in revised targets (CRF-RT)
Description: Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial and recurrent fibular nerves and the infra-patellar branch of the saphenous nerve. The participant will not be able to follow the procedure.
Study: NCT06571578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold Inspiratory muscle trainer
Description: threshold inspiratory muscle trainer device Each subject will breathe through a separate mouthpiece through attach the mouthpiece firmly While putting a nose clip and inhale deeply through the mouthpiece to generate an inspiratory pressure greater than the indicated presetting threshold pressure to compress the spring and open the valve. Using High - intensity interval training technique
Study: NCT03289260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Description: Patients receive topical Imiquimod therapy for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Patients receive topical Doritin therapy for 12 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fulguration
Description: Surgical Excision and Fulguration of condyloma

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fulguration
Description: Surgical Excision and Fulguration of condyloma
Study: NCT06571578

Intervention type: OTHER
Group type: OTHER
Intervention: posture correction exercises
Description: conventional exercise consists of~* Cervical isometric exercises will be performed in the sitting position by resisting at the forehead (cervical ﬂexion, extension, rotation and side bending) for 10 seconds with 15 seconds breaks between holds with 10-15 repetitions in a progressive manner 3time/week for 12 weeks.~* Postural correction exercise consists of gently rolling of pelvis forward to an upright neutral sitting position, followed by scapular correction and occipital lift. Also, for the sub-occipital muscles stretching~* stretching exercises for scalene and levator muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: posture correction exercises
Description: conventional exercise consists of~* Cervical isometric exercises will be performed in the sitting position by resisting at the forehead (cervical ﬂexion, extension, rotation and side bending) for 10 seconds with 15 seconds breaks between holds with 10-15 repetitions in a progressive manner 3time/week for 12 weeks.~* Postural correction exercise consists of gently rolling of pelvis forward to an upright neutral sitting position, followed by scapular correction and occipital lift. Also, for the sub-occipital muscles stretching~* stretching exercises for scalene and levator muscles
Study: NCT06571071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-Stress and Chill Gummies-U001
Description: Two gummies in sequence daily after meal for 60 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-Stress and Chill Gummies-I001
Description: Two gummies in sequence daily after meal for 60 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gummies-001
Description: Two gummies in sequence daily after meal for 60 days
Study: NCT05295953

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TBS
Description: Four sessions of TBS at 120 % resting motor threshold, delivered using MagVenture B65 A/P coil, each lasting 10 minutes and separated by 50 minutes intervals. Targeting will be done using neuronavigation and processed resting state brain scan.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: Four sessions of sham TMS delivered using MagVenture B65 A/P coil.
Study: NCT05280379

Intervention type: OTHER
Intervention: no intervention will take place
Description: no intervention will take place

Intervention type: OTHER
Intervention: no intervention will take place
Description: no intervention will take place
Study: NCT04830644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod orally twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally twice a day
Study: NCT03950037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole; 15 mg/k/d divided in two doses (morning and evening), for 30 days, with a ceiling in 1200 mg/d.
Study: NCT06239116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)
Study: NCT06202937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother Baby Yoga
Description: Fragile Baby Perception Syndrome, Maternal Attachment, Depression-Anxiety-Stress Level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention:control
Description: the control group received the usual care
Study: NCT05168644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide Inhalation Powder
Description: Investigational drug will be supplied as capsules, each capsule contains 0.25 mg or 1 mg of Niclosamide Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
Study: NCT06340789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Benzoate 2gram/day
Description: the add-on sodium benzoate with conventional pharmacological treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the add-on placebo with conventional pharmacological treatment
Study: NCT06239116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C: RM-718
Description: Multiple ascending doses of RM-718 (specific to Part C dose cohorts)
Study: NCT06347822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy Session
Description: Single-session intervention (SSI) based on acceptance and commitment therapy (ACT) and solution-focused brief therapy (SFBT) principles
Study: NCT06021600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given by PO and Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given by PO and Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given by PO and Given by IV (vein)
Study: NCT05720611

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Digitally delivered gardening and healthy eating course
Description: The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digitally delivered gardening and healthy eating course
Description: The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.
Study: NCT06235099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 PSMA I&T
Description: Radiopharmaceutical PET imaging tracer injected intravenously for the detection of PSMA expression.
Study: NCT05079464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: All participants randomized to tDCS will receive active tDCS

Intervention type: OTHER
Group type: OTHER
Intervention: tDCS
Description: All participants randomized to tDCS will receive active tDCS

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Participants will exercise at Toronto Rehab.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will exercise at Toronto Rehab.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham stimulation
Description: The same procedure for tDCS will be used for the sham condition, except without active current.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham stimulation
Description: The same procedure for tDCS will be used for the sham condition, except without active current.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Exercise education/ treatment as usual will include routine advice about physical activity.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Exercise education/ treatment as usual will include routine advice about physical activity.
Study: NCT05576350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Based Alcohol Monitoring (SAM)
Description: Smartphone-based alcohol monitoring (SAM) using mobile breathalyzers and surveys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Based Alcohol Monitoring (SAM)
Description: Smartphone-based alcohol monitoring (SAM) using mobile breathalyzers and surveys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Based Alcohol Monitoring (SAM)
Description: Smartphone-based alcohol monitoring (SAM) using mobile breathalyzers and surveys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tracking and Reducing Alcohol Consumption (TRAC)
Description: The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage drinking. It requires four 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the four sessions of intervention content, participants will complete smartphone-based self-monitoring of alcohol consumption, which will be discussed during intervention sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tracking and Reducing Alcohol Consumption (TRAC)
Description: The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage drinking. It requires four 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the four sessions of intervention content, participants will complete smartphone-based self-monitoring of alcohol consumption, which will be discussed during intervention sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAC-ER
Description: Ecological momentary interventions (EMI) use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use.
Study: NCT06205095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII
Description: Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®.
Study: NCT05347914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will be taught a mindfulness exercise and will be instructed to use this exercise (following a mobile app) whenever they experience a food craving to eat for non-homeostatic reasons.
Study: NCT05927246

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: 12 lead ecg for each participant

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: 12 lead ecg for each participant
Study: NCT03988439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Topical
Study: NCT05035641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
Study: NCT05418790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TASSO device
Description: During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.